Arterys

In 2017, Arterys got FDA approval to commercialize a first-of-its-kind AI “doctor” capable of diagnosing heart problems from looking at an MRI. By automating image-analysis tasks that radiologists typically perform manually, it can reduce total evaluation time from 30 minutes to 15 seconds. In February 2018, versions of the software that detect and track tumors and lesions in MRI and CT scans of the lungs and liver also got the agency’s go-ahead. Arterys’s AI-as-a-service platform is cleared to operate in nearly 100 countries and is currently used at about 100 hospitals worldwide, says CEO Fabien Beckers, who cofounded the company in 2011.